A PCSK9 inhibitor injection with the longest outcomes record in its class, with fewer heart attacks and strokes. Prescribed and managed through the Lipid Management Program.
Form
Injection pen
Dosing
Every 2 or 4 weeks
Works with
Your statin
Filled at
Your pharmacy
ACCESS THROUGH THE PROGRAM
ACCESS THROUGH THE PROGRAM
Membership billed annually. Repatha is prescribed only if appropriate and filled at your local pharmacy.
60+ biomarkers tested
A clinician who sets your targets
Retesting & adjustments
HSA/FSA eligible
Repatha blocks PCSK9, a protein that breaks down the liver’s LDL receptors. With more receptors left, your liver clears more LDL (“bad”) cholesterol from your blood. Added to a statin in the FOURIER trial, it lowered LDL 59% further and cut heart attacks and strokes by 20%.
A small injection under the skin with a prefilled pen, every 2 weeks or once a month, at home. Your care team walks you through your first dose.
Your Lipid Management Program membership is $75/mo, billed annually, and covers testing, your clinician and coaching. If your clinician prescribes it, the medication is billed separately: your prescription goes to your local pharmacy, where insurance may apply. We don’t sell PCSK9 inhibitors or profit from them.
Your clinician reviews your history, labs and current medications first. A prescription is only written if it’s clinically appropriate, so it isn’t guaranteed, and your clinician may recommend a different option.
Why PCSK9 inhibitors
For decades, statins set the limit on how low harmful LDL cholesterol could go. PCSK9 inhibitors broke through it.
Scientists found people whose genes naturally switch off a protein called PCSK9. Their LDL runs low for life, and they have far fewer heart attacks. PCSK9 inhibitors were built to give everyone that same protection.¹
Your cardiovascular trajectory
Illustrative only. Not a prediction of individual outcomes.
Up to 60%
On top of a statin, LDL drops up to 60% further, and ApoB falls with it. Levels once out of reach become normal.²
FOURIER
20%
Added to a statin in a 27,000-person trial, with the benefit growing the longer people stayed on it.³
FOURIER · 27,000+ people
Plaque
Added to a statin, PCSK9 treatment helped existing plaque in the arteries regress. It lowers Lp(a) too.⁴
GLAGOV
The earlier LDL comes down and the longer it stays there, the bigger the benefit. That’s what we build your protocol around.
Your clinician reviews your labs and cardiovascular risk and decides whether treatment is appropriate.
Most care stops at LDL. We look at cholesterol particles, inflammation, and metabolic health together, because that’s how heart disease actually works.
Particles carrying cholesterol slip into the artery wall and stay there. Lp(a) is the genetic version most people have never tested.
Inflammation turns quiet buildup into active plaque, even when LDL looks fine.
Insulin resistance damages the artery lining and stiffens it over time. Fasting insulin can flag it years before blood sugar rises.
Your first panel sets the starting point.
See how your markers respond.
Your clinician fine-tunes your plan.
Our clinicians and coaches turn the latest research on heart disease and aging into a protocol built for your biology, then adjust it until you hit your target.
Clinicians who prescribe, combine, and fine-tune your treatment around your labs and goals.
Coaches with advanced degrees, guiding nutrition, training, and sleep around your results.
As new cardiovascular research emerges, your protocol keeps pace, so you get the best outcome possible.
HSA/FSA eligible
Advanced testing, a clinician, coaching, and retesting, all in one program.
$75/month
Billed annually
4.7 on Trustpilot20,000+ patientsYour treatment options
Your clinician prescribes. Your local pharmacy fills. Medications are billed separately.
The longest outcomes record in its class, with fewer heart attacks and strokes.
The first oral PCSK9 inhibitor, for people who would rather not inject.
A once-monthly injection with a cash option when insurance won’t cover it.
A proven daily statin that lowers LDL and the risk of heart attack and stroke.
A daily statin dosed around your risk, kidney function, and other medications.
Blocks cholesterol absorption in the gut, often paired with a statin.
Independent prescribing decisions · We don’t sell PCSK9 inhibitors or profit from them. A clinician decides every prescription.
A cholesterol-lowering medication that blocks a protein called PCSK9. With less PCSK9, your liver keeps more of the receptors that clear LDL ("bad") cholesterol from your blood. It's available as an injection (Repatha, Lerochol) or a once-daily pill (Lipfendra).
Usually not. PCSK9 inhibitors are often added to a statin to lower LDL further, and they can be used on their own if statins don't agree with you. Don't stop or change any medication without talking to your clinician first.
Only if it's clinically appropriate. Your clinician reviews your history, lab results, and current medications before prescribing anything, so a prescription isn't guaranteed. You're welcome to share your preferences, and your clinician weighs them alongside your results, risk, and goals.
Your membership covers biomarker testing, your clinical team, ongoing guidance, and follow-up retesting. Medications aren't included and are billed separately.
Your clinician sends your prescription to your local pharmacy, where insurance may apply, or to the manufacturer's program for Lerochol. We don't sell PCSK9 inhibitors or profit from them. Statins and ezetimibe can be filled through our pharmacy partner.
No. It's a separate cash price paid directly to the manufacturer's program. Your $75/mo membership covers testing and clinical care.
Follow-up testing shows how your numbers respond, and you review the results with your clinician. Your plan is adjusted over time based on what they show.
Possibly. A normal LDL doesn't always mean low risk: ApoB, Lp(a), inflammation, and metabolic health can tell a different story. Testing helps you and your clinician see the full picture.
